

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>van der Baan Bastiaan Jeroen</u> _____ (Last) (First) (Middle) HOGEWEG 4-H _____ (Street) AMSTERDAM P7 P71098CB _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</u> [ LIXT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>President and CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) 09/26/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Options to Purchase Common Stock	\$1.95	09/26/2023		A		250,000		(I)	09/26/2028	Common 250,000	\$0 <sup>(1)</sup>	250,000	D	
Options to Purchase Common Stock	\$5.88	06/30/2023		A		10,000			06/30/2023 06/30/2028	Common 10,000	\$0	10,000	D	
Options to Purchase Common Stock	\$7.4	06/17/2022		A		25,000			06/17/2022 06/17/2027	Common 25,000	\$0	25,000	D	

**Explanation of Responses:**

1. In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested.

**Remarks:**

NOTE: Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of common stock set forth above for all transactions entered into prior to that date have been adjusted to reflect the reverse stock split.

/s/ Bastiaan van der Baan 09/27/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.